SCHEMBL3019240

SCHEMBL3019240

COC(=O)c1cc(S(=O)(=O)Cl)c(C(=O)OC)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.46
MAPT P10636 7/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 2/20 0.45
PPARG P37231 1/20 0.45
NCOA2 Q15596 1/20 0.45
NCOA1 Q15788 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
OPRD1 P41143 1/20 0.41
RAB9A P51151 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
ATM Q13315 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KMT2A Q03164 3/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 1/20 0.40
HPGD P15428 4/20 0.40
MAPK1 P28482 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8779802 0.93 KDM4E (0.40) KDM4EMAPTLMNANPSR1PPARG
SCHEMBL3016567 0.85 MAPT (0.40) KDM4EMAPTLMNANPSR1PPARG
SCHEMBL9403869 0.84 KDM4E (0.47) KDM4EMAPTLMNANPSR1PPARG
SCHEMBL25202606 0.83 MAPT (0.38) KDM4EMAPTLMNANPSR1PPARG
SCHEMBL11014523 0.80 MAPT (0.43) KDM4EMAPTNPSR1L3MBTL1GAA
SCHEMBL5839960 0.79 C1S (0.43) KDM4EMAPTLMNANPSR1PPARG
SCHEMBL3060116 0.78 DAO (0.44) KDM4EMAPTLMNANPSR1GLA
SCHEMBL9403870 0.78 KDM4E (0.41) KDM4EMAPTLMNANPSR1PPARG
SCHEMBL4360547 0.77 MAPT (0.58) KDM4EMAPTLMNANPSR1RAB9A
SCHEMBL2305822 0.75 MCL1 (0.51) KDM4EMAPTLMNANPSR1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-0770599-A1 PROCESS FOR THE PREPARATION OF AROMATIC OR HETEROAROMATIC SULFONYL HALIDES SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1997-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM4E 4398/4885MAPT 18/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.